New Effort for Lyme Disease Vaccine Draws Early Fire

In March, Valneva SE , a company based in France, announced initial phase-one clinical trial results after testing its proposed vaccine in 180 healthy adults who took the vaccine with no serious side effects. The study also showed that the vaccine stimulated an immune response, says David Lawrence, chief financial officer of the company.